BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic antibodies while eking out its cash to cover a slew of clinical readouts over the next couple of years.
